Spring Bank Pharmaceuticals to Host Conference Call to Discuss Top-Line Results from the Initial Cohort of the Phase 2a Segme...
May 22 2017 - 4:00PM
Spring Bank Pharmaceuticals, Inc. (Nasdaq:SBPH), a clinical-stage
biopharmaceutical company developing novel therapeutics for the
treatment of viral infections, cancer, and inflammatory diseases,
announced today that the company’s management team plans to host a
conference call on Wednesday, May 24, 2017, at 8:00 a.m. ET, to
discuss top-line results from the initial 25mg monotherapy dosing
cohort of the Phase 2a segment of its ACHIEVE trial, a global,
placebo-controlled, sequential-cohort, double-blind Phase 2
clinical trial for chronic Hepatitis B virus (HBV).
The conference call may be accessed by dialing
(866) 294-9216 for U.S. callers and (346) 406-0955 for
international callers five minutes prior to the start of the call
and providing the conference ID: 27754723. Additionally, the live,
listen-only webcast of the conference call can be accessed by
visiting the Investors & Media section of the Company’s website
at www.springbankpharm.com. A replay of the conference call will be
available following the call and may be accessed by visiting Spring
Bank’s website.
About Spring Bank
Pharmaceuticals
Spring Bank Pharmaceuticals is a clinical-stage
biopharmaceutical company engaged in the discovery and development
of a novel class of therapeutics using its proprietary small
molecule nucleic acid hybrid (SMNH) chemistry platform. SMNH
compounds are small segments of nucleic acids that the company
designs to selectively target and modulate the activity of specific
proteins implicated in various disease states. The company is
developing its most advanced SMNH product candidate, SB 9200, for
the treatment of viral diseases, including hepatitis B virus (HBV).
SB 9200 has been designed to selectively activate within infected
cells the cellular proteins, retinoic acid-inducible gene 1, or
RIG-I, and nucleotide-binding oligomerization domain-containing
protein 2, or NOD2, which have been implicated in the body's immune
response to viral infections. Spring Bank Pharmaceuticals is also
developing other SMNH product candidates, including SB 11285,
the company’s lead immunotherapeutic agent for the treatment of
selected cancers through the activation of the STimulator of
INterferon Genes, or STING, pathway. For more information, please
visit www.springbankpharm.com
Contact:
Spring Bank Pharmaceuticals, Inc.
Jonathan Freve
Chief Financial Officer
(508) 473-5993
jfreve@springbankpharm.com
Spring Bank Pharmaceutic... (NASDAQ:SBPH)
Historical Stock Chart
From Apr 2024 to May 2024
Spring Bank Pharmaceutic... (NASDAQ:SBPH)
Historical Stock Chart
From May 2023 to May 2024